Connect with us

Sanofi says good results from flu vaccine with mRNA booster study

HBS Reporting

Sanofi says good results from flu vaccine with mRNA booster study

Sanofi says good results from flu vaccine with mRNA booster study

PARIS, Oct 7 (Reuters) – French healthcare company Sanofi (SASY.PA) said on Wednesday that it had found positive results from the first study into a high-dose influenza vaccine with a COVID-19 mRNA booster.

Sanofi said the interim results from the study of Sanofi’s Fluzone High-Dose Quadrivalent vaccine with Moderna’s (MRNA.O) COVID-19 mRNA investigational booster dose showed the vaccines had similar immunogenicity responses and a similar safety and tolerability profile.

“These positive results could facilitate the implementation of Northern Hemisphere influenza and COVID-19 booster vaccination campaigns, especially in this high-risk population,” said Dr. Michael Greenberg, North America Medical Head for Vaccines at Sanofi.

Continue Reading
You may also like...
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

More in HBS Reporting